Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 5:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 33,600 matching trials from the live ClinicalTrials.gov search.
Terminated Phase 2 Interventional Results available

A Study of IMR-687 in Subjects With Sickle Cell Disease

NCT04474314
Conditions
Sickle Cell Disease
Interventions
IMR-687, Placebo
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 11 more
Conditions
Seizures, Epilepsy
Interventions
levetiracetam
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 30 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Episodic Migraine, Migraine With Aura, Migraine Without Aura, Migraine
Interventions
Mi-Helper
Device
Lead sponsor
CoolTech LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Leukemia
Interventions
dasatinib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Multiple Myeloma
Interventions
CC-92328
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tampa, Florida + 2 more
Conditions
Hematologic Malignancies
Interventions
UCB and HPDSC
Procedure
Lead sponsor
Celgene Corporation
Industry
Eligibility
Up to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Iron Overload, Sickle Cell Disease, Other Anemias
Interventions
Deferiprone, Deferoxamine
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
2 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Oakland, California • Chicago, Illinois • New Orleans, Louisiana + 4 more
Conditions
Cutaneous Lichen Planus
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more
Conditions
Myelofibrosis
Interventions
Simtuzumab, Ruxolitinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Scottsdale, Arizona • Stanford, California • St Louis, Missouri + 4 more
Conditions
Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 14 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive, Diffuse Large B-Cell Lymphoma Unclassifiable, Intravascular Large B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab, Vincristine Sulfate
Drug · Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois
Enrolling by invitation No phase listed Observational

Posterior Cervical Fixation Study

NCT04770571
Conditions
Degenerative Disc Disease, Craniocervical Injuries, Cervical Radiculopathy, Cervical Disc Disease, Cervical Fusion, Cervical Spine Disease, Cervical Myelopathy, Cervical Instabilities Spine, Thoracic Injury
Interventions
observational study
Device
Lead sponsor
NuVasive
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Orange, California • Hartford, Connecticut • Hyattsville, Maryland + 4 more
Conditions
Alzheimer's Disease
Interventions
PPI-1019 (APAN)
Drug
Lead sponsor
PRAECIS Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Juan Capistrano, California
Conditions
Depressive Disorder, Major
Interventions
SEP-225289, Venlafaxine, placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
51
States / cities
Little Rock, Arkansas • Arcadia, California • Beverly Hills, California + 43 more
Conditions
Diabetes Mellitus, Type 2
Interventions
KQ-791, Placebo
Drug
Lead sponsor
Kaneq Bioscience Limited
Other
Eligibility
18 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Tempe, Arizona • Miami, Florida • Orlando, Florida + 1 more
Conditions
Upper Gastrointestinal Mucosal Damage
Interventions
acetylsalicylic acid
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
50 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
6
States / cities
Jupiter, Florida • South Miami, Florida • Oklahoma City, Oklahoma + 3 more
Conditions
Systemic Sclerosis
Interventions
Pirfenidone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • Redwood City, California + 14 more
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
Conditions
Parkinson's Disease
Interventions
Accordion Pill™ Carbidopa/Levodopa, Sinemet®, Placebo -AP-CD/LD, Placebo- Sinemet
Drug
Lead sponsor
Intec Pharma Ltd.
Industry
Eligibility
30 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

NCT05664334
Conditions
Healthy
Interventions
IVX-121, IVX-241, Placebo, MF59®
Biological · Other
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more
Terminated Not applicable Interventional Results available

Trial on Endovascular Aneurysm Management

NCT00537134
Conditions
Brain Aneurysm
Interventions
Embolization, coiling
Device
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Phoenix, Arizona • Boston, Massachusetts • Brooklyn, New York + 3 more
Terminated Phase 2 Interventional Results available

Maraviroc in Rheumatoid Arthritis

NCT00427934
Conditions
Arthritis, Rheumatoid
Interventions
Maraviroc, Maraviroc Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
21
States / cities
Huntington Beach, California • San Francisco, California • Hamden, Connecticut + 14 more
Conditions
Delayed Onset Muscle Soreness, DOMS
Interventions
SST-0225, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Hollywood, Florida • South Miami, Florida • Springfield, Missouri